Jill Feldman on creating a patient-friendly lung cancer lexicon

Jill Feldman shared a post by Oncogene Cancer Research on X, adding:

“Here I discuss my presentation AT WCLC24 on creating a patient-friendly lung cancer lexicon with Lung Cancers Today & the challenge patients & families face when navigating the highly technical language of cancer research. The goal was not to change how researchers talk to each other but to empower patients & families to understand the research & be part of the conversation.

For example, simplifying key scientific terms. The lexicon includes terms like using “side effect” instead of “adverse event,” a clearer and more accessible choice. The patient-friendly lexicon is a step toward making lung cancer research more inclusive & understandable, helping patients & families feel comfortable and confident in their treatment decisions. I hope this initiative will inspire others to adopt more compassionate & inclusive language.”

Quoting Oncogene Cancer Research:

“Just like research and treatments have advanced, the language that we use needs to advance to be more inclusive to empower patients and also to be more compassionate and nonjudgmental,” says Jill Feldman. Important to advance the language we use in lung cancer.”

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.